Applying real-world evidence (RWE) to regulation and reimbursement is an emerging field in pharma, and Roche stands at the forefront with its recent acquisition of Flatiron Health, Inc. and their electronic health records database.
At the annual meeting of the American Society of Clinical Onoclogy, Roche Pharmaceuticals CEO Daniel O’Day outlined the company’s efforts in using RWE in control arm analysis for reimbursement negotiations, and spoke of the prospects for using RWE in clinical development. Learn more about the evolving field of RWE in this essential article from Pink Sheet.
At the annual meeting of the American Society of Clinical Onoclogy, Roche Pharmaceuticals CEO Daniel O’Day outlined the company’s efforts in using RWE in control arm analysis for reimbursement negotiations, and spoke of the prospects for using RWE in clinical development. Learn more about the evolving field of RWE in this essential article from Pink Sheet.
